Complex chromosomal rearrangements induce embryonic chromosomal imbalance and significantly compromise reproductive outcomes Authors: Yueyun Lan, Xihe Deng, Sheng He, Jingsi Luo, Jiasun Su, Wei Li, Chaofan Zhou, Xianglian Tang, Yuan Wei, Minpan Huang, Jingrong Luo, Jinhui Shu, Caizhu Wang, Xin Zhao, Hong Zhou, Peng Huang Published: 2026 ABSTRACT AbstractThis study evaluated Preimplantation Genetic Testing for Structural Rearrangements (PGT‑SR) outcomes in carriers of complex chromosomal rearrangements (CCRs). Four CCR couples underwent PGT‑SR, and 20 karyotypically normal couples underwent Preimplantation Genetic Testing for Aneuploidy (PGT‑A) as controls. Embryo biopsies were analyzed by next‑generation sequencing (NGS), and Mapping Allele with Resolved Carrier Status (MaReCs) was used for breakpoint mapping. Literature data from 31 additional CCR carriers (222 embryos) were also summarized. Among the four CCR couples in this study, 14 blastocysts were biopsied. The high‑quality blastocyst rate (57.1%, 8/14) and euploidy rate (14.29%, 2/14) were significantly lower than in controls (71.5% and 42.37%, respectively; P < 0.05). In the literature cohort of 222 embryos, for CCR types A (three‑way), B (double two‑way), and C (exceptional), the high‑quality blastocyst rates (37.50%, 44.44%, and 32.91%) and chromosomal abnormality rates (86.25%, 92.06%, and 88.61%) showed no significant differences; the overall euploidy rate (11.26%) was significantly lower than that in the PGT‑A control group (42.37%, P < 0.001). In conclusion, CCR carriers show impaired embryonic potential and markedly lower euploidy rates. While Type B CCR embryos have good morphology, their genetic normality is extremely poor, ruling out morphology-only selection. Instead, PGT-SR combined with high-resolution breakpoint mapping is required to reliably identify viable embryos for healthy pregnancy.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40834-026-00461-z.Keywords: Complex chromosomal rearrangements, Mapping allele with resolved carrier status, Preimplantation genetic testing for aneuploidy, Preimplantation genetic testing for structural rearrangements, Embryo Introduction Chromosomal rearrangements such as translocations and inversions disrupt meiotic pairing and segregation [1], thereby impairing germ cell development, reducing viable gamete formation, and compromising precise genetic transmission. A major consequence is sex chromosome aneuploidy, which directly impairs gonadal development and reproductive function [2]. Among these various rearrangements, complex chromosomal rearrangements (CCRs) represent a particularly intricate subset, involving at least two chromosomes and three breakpoints [3] that typically originate from homologous sequences on non‑homologous chromosomes and are rejoined via non‑allelic homologous recombination [4]. Through this process, chromosomal segments are exchanged or inserted between non‑homologous chromosomes, generating novel derivative chromosomes. Reproductive outcomes are therefore critically determined by the structural balance and phenotypic effects of the rearrangement, with rearrangement complexity positively correlated with the risk of phenotypic abnormalities [5]. Given the profound influence of rearrangement complexity on both structural integrity and phenotypic risk, CCRs have been further categorized into three distinct subtypes based on their structural characteristics: type A (three‑way rearrangements), type B (double two‑way translocations), and type C (exceptional CCRs) [6]. Type A, the most common, involves breakage and reciprocal fragment exchange among three chromosomes (e.g., A→B, B→C, C→A). These rearrangements are predominantly familial and can be transmitted across generations, likely facilitated by homologous sequences such as low‑copy repeats at the breakpoints [7]. Type C typically involves 4 to 7 chromosomes with up to 15 breakpoints, reflecting extreme structural complexity [8]; these are mostly de novo events, possibly arising from aberrant DNA repair or cell cycle checkpoint failure [6]. Type B involves segment exchange between two or more chromosome pairs (e.g., A↔B and C↔D) [9]. Notably, the origin and inheritance patterns of CCRs differ substantially by subtype. Most CCRs occur de novo, while heritable cases tend to involve fewer chromosomes and breakpoints and exhibit greater structural stability [6]. In prenatal diagnosis, most CCRs are maternally inherited, likely due to aberrant repair of chromosomal breaks during maternal germ cell meiosis, leading to balanced CCRs [10]. Conversely, de novo unbalanced CCRs detected in newborns are predominantly of paternal origin [11], probably because of an increased predisposition to unbalanced alterations during paternal germ cell maturation [12]. Such distinct inheritance patterns underscore the necessity of precise preimplantation genetic testing (PGT) for CCR carriers. To address these implications, Preimplantation Genetic Testing for Structural Rearrangements (PGT‑SR) is the primary tool for CCR carriers. A recent advance, Mapping Allele with Resolved Carrier Status (MaReCs), enables breakpoint localization with ~ 200 kb precision [13], allowing accurate discrimination between normal and balanced‑carrier embryos and reducing transmission risk [14]. When embryonic status remains ambiguous, primary copy number variations (CNVs) screening identifies and excludes embryos with microdeletions/duplications, minimizing pregnancy failure due to microstructural anomalies. Using MaReCs, we found that CCRs involving multiple chromosomal segments significantly increase embryonic chromosomal abnormalities, explaining the severely compromised developmental potential of such embryos. Methods Study design This study enrolled four CCR-affected couples undergoing PGT‑SR (designated as cases 1–4) and 20 couples undergoing Preimplantation Genetic Testing for Aneuploidy (PGT‑A) as controls. All participants were recruited from the Reproductive Medicine Center of Guangxi Maternal and Child Health Hospital between July 2021 and September 2024. To minimize confounding factors, each participant underwent comprehensive clinical assessments to rule out endocrine, metabolic, or reproductive system disorders. Key parameters recorded per IVF cycle included maternal age, the number and quality of retrieved oocytes, the incidence of binucleated oocytes, and detailed assessments of embryo morphology. Cytogenetic analysis Peripheral blood samples from the couples were cultured and treated with colchicine to inhibit spindle formation and arrest cells at metaphase. The harvested cells were then subjected to hypotonic treatment, centrifugation, fixation, and Giemsa staining to prepare chromosome spreads for G‑banding analysis. For each sample, 20 metaphases were analyzed (extended to 50 if chimerism was suspected). Karyotype descriptions strictly followed the International System for Human Cytogenetic Nomenclature (ISCN 2024) [15]. Protocol for ovulation induction and fertilization A controlled ovarian stimulation protocol was selected based on ovarian reserve assessment, which included age, BMI, basal hormone levels, and antral follicle count. Fertilization status and early developmental potential were evaluated 18–20 h post‑fertilization by examining the number and morphology of pronuclei. Blastocyst biopsy Fertilized oocytes were cultured at 37 °C in 6% CO₂. Cleavage-stage embryos were assessed at 48 h post‑fertilization and then further cultured to days 5–7 for blastocyst formation. Blastocysts graded as ≥4BB according to the Gardner system were considered high‑quality. Those achieving a grade of ≥3BC underwent trophectoderm biopsy (six to eight cells) on day 5 or 6 and were immediately vitrified. Whole-genome amplification (WGA) Trophectoderm biopsy samples were amplified using the MALBAC kit (Yikon Genomics, Shanghai, China). Samples were incubated at 50 °C for 20 min and 80 °C for 10 min, then held at 4 °C. The amplification master mix (60 µL buffer + 2 µL enzyme) was aliquoted into reaction tubes. The cycling protocol was: initial denaturation at 94 °C for 3 min; 8 cycles of amplification (94 °C for 20 s, 58 °C for 30 s, 72 °C for 2 min); 17 cycles of linear amplification (94 °C for 3 s, 58 °C for 15 s, 72 °C for 2 min); final extension at 72 °C for 5 min; and hold at 4 °C. Products were stored at 4 °C. Next-generation sequencing (NGS): CNVs analysis For CNVs analysis, genomic DNA was randomly fragmented using a transposase to a size range of 300–500 bp, followed by end repair, A‑tailing, adapter ligation, and 8 cycles of PCR amplification to achieve a concentration of ≥ 2 nM. The purified library was subjected to paired‑end sequencing on the Illumina MiSeq platform. Reads were trimmed of adapters and low‑quality bases, aligned to the hg19 reference genome, and only uniquely mapped reads were retained. Reads were then counted in 1,000‑kb bins, GC‑corrected, and normalized. CNVs were identified using Perl scripts and visualized with R. Breakpoint mapping and haplotype analysis for carrier detection in balanced translocations To map translocation breakpoints, embryonic chromosomal status was first assessed using long‑read sequencing (CCS). Embryos with unbalanced translocations (e.g., partial deletions or duplications) served as references. Breakpoints were localized using a hierarchical sliding‑window approach. First, a trimean‑based scan (10 intervals, 100‑kb step) defined a Level 1 region between diploid threshold deviations. Then, a mean‑based calculation (3 intervals, 100‑kb step) pinpointed the breakpoint to a 200‑kb resolution by identifying two consecutive deviating intervals. For haplotype analysis, we genotyped 60 informative single nucleotide polymorphisms (SNPs) within a 1‑Mb breakpoint region in the family trio (heterozygous in one parent and homozygous in the other). A translocation‑associated haplotype was constructed using SNPs linked to the reference embryo. Carrier status of balanced embryos was determined by assessing the heterozygosity and phase of these SNPs against the reference haplotype [16]. Validation of MaReCs results through prenatal diagnosis To validate MaReCs results, amniocentesis was performed at 18–20 gestational weeks on pregnancies achieved after assisted reproduction. Collected cells were analyzed by karyotyping and chromosomal microarray. Statistical methods Rate comparisons were performed using the chi‑square test, or Fisher’s exact test when expected frequencies were < 5. Age was compared using the Mann‑Whitney U test. A P‑value < 0.05 was considered statistically significant. All analyses were conducted with SPSS 20.0. Results Embryonic outcomes in four CCR carriers versus PGT‑A controls G‑banding analysis revealed that one partner in each couple carried balanced CCRs, while the other had a normal karyotype (Table 1). Cases 2, 3, and 4 involved three‑way chromosomal translocations. Case 1 exhibited both a reciprocal translocation between chromosomes 9 and 14 (breakpoints at 9q32 and 14q11.2; Fig. 1) and an interstitial insertion of 14q11.2–q13 into 9q32. Based on CNV analysis of informative embryos, MaReCs successfully mapped breakpoints in all four families, although the three‑chromosome involvement in Families 3 and 4 prevented detection of carrier embryos (Supplementary Fig. 1). Table 1Karyotype of four CCR casesCaseFemale age (years)Karyotype Kryotypes of partnersPGT-SR cycleD5 embryo ratingD6 embryo ratingTransferredPregnancy outcome13346,XX,ins(9;14)(q32;q11.2q13),t(9;14)(q32;p11.2)46,XY11 4AB, 1 4BB023546,XX,t(1;14;5)(p32;q11.2;q13)46,XY11 4AA1 4BB032546,XX,t(5;9;8)(q33.2;q21.2;q24.1)46,XY22 4BC, 1 4CB2 4BC1142946,XY,t(1;6;13)(q21;q22.3;q22.1)46,XX14 4AA, 1 3AB10 Karyotype of four CCR cases Karyotype analysis of Case 1 in this study The mean age of the four CCR carriers was 30.05 ± 4.44 years, comparable to that of the PGT‑A controls (32.55 ± 3.03 years; Mann‑Whitney U test, P = 0.431). The CCR carriers underwent a total of five PGT‑SR cycles: Cases 1, 2, and 4 each had one cycle, and Case 3 had a second cycle due to no blastocyst formation in the first. A total of 14 blastocysts were biopsied. By Gardner scoring on day 5/6, 8/14 (57.1%) were high‑quality, and karyotyping revealed 2 euploid embryos (14.29%). Among the 14 blastocysts, 12 were abnormal: aneuploidy (2/14, 14.29%), segmental abnormalities (9/14, 64.29%), and mixed abnormalities (1/14, 7.14%), defined as embryos with both segmental abnormalities and aneuploidy (Fig. 2). Notably, three abnormal embryos carried de novo abnormalities unrelated to parental translocations (Supplementary Table 1). Analysis of chromosomal abnormality types in published CCRs and our PGT‑A control group In the PGT‑A control group (all couples with normal karyotypes), 23 cycles produced 137 embryos, of which 118 underwent genetic testing (19 were cryopreserved without testing). Of the 137 embryos, 98 (71.5%) were high‑quality. Among the 118 tested embryos (Supplementary Table 2), 50 were euploid (42.37%). Abnormalities included aneuploidy (20/118, 16.95%), segmental abnormalities (33/118, 27.97%), mixed abnormalities (12/118, 10.17%), polyploidy (2/118, 1.69%), and one amplification failure (0.85%) (Fig. 2). The small sample size may explain the lack of a significant difference in high‑quality blastocyst rate between the CCR and PGT-A control groups (57.1% vs. 71.5%, P = 0.352). In contrast, the euploidy rate was significantly lower in the CCRs group (14.29% vs. 42.37%, P = 0.047). Embryonic outcomes in literature-summarized CCRs cases versus PGT‑A controls Given the rarity of CCR carriers, we systematically searched PubMed for published PGT studies on CCR embryos [17–19] to expand the sample size and investigate the impact of CCRs on embryonic molecular karyotypes. A total of 31 CCR carriers were included and divided by structural type into Group A (n = 11), B (n = 7), and C (n = 13) (Supplementary Table 3), yielding 222 embryos for analysis (Group A: 80, B: 63, C: 79). The four CCR families from the present study were analyzed separately and thus not included in this grouping, whereas Table 2 summarizes the embryonic outcome data of CCR carriers from the present study and previously published literature. Table 2Summary of embryo outcomes in CCR carriers from the present study and previously published literatureCaseNumber of casesNumber of blastocystsHigh‑quality blastocyst rateEuploidy rateSegmental abnormalitiesMixed abnormalitiesAneuploidyAmplification failurePresent study (authors’ cases)41457.1% (8/14)14.29% (2/14)64.29% (9/14)7.14% (1/14)14.29% (2/14)0%Literature summary [17–19] *3122237.84% (84/222)11.26% (25/222)58.56% (130/222)21.17% (47/222)6.76% (15/222)2.25% (5/222)* Literature data were extracted from Hu et al. [17], Gang Li et al. [18] and Dun Liu et al. [19]. Summary of embryo outcomes in CCR carriers from the present study and previously published literature * Literature data were extracted from Hu et al. [17], Gang Li et al. [18] and Dun Liu et al. [19]. By day 6 post-fertilization, 84/222 blastocysts (37.84%) were high-quality, significantly lower than in the PGT-A control group (71.5%, P < 0.001). The high-quality blastocyst rates for Groups A, B, and C were 37.50% (30/80), 44.44% (28/63), and 32.91% (26/79), respectively, with no significant pairwise differences (37.50% vs. 44.44%, P = 0.493; 37.50% vs. 32.91%, P = 0.619; 44.44% vs. 32.91%, P = 0.169). Chromosomal abnormality rates were similarly high: 86.25% (69/80) in Group A, 92.06% (58/63) in Group B, and 88.61% (70/79) in Group C, also showing no significant pairwise differences (86.25% vs. 92.06%, P = 0.301; 86.25% vs. 88.61%, P = 0.812; 92.06% vs. 88.61%, P = 0.579). We next analyzed the incidence of abnormalities involving the same translocated chromosomes as the parents. Because Gang Li et al. [18] did not clearly provide specific chromosomal information for cases with abnormalities involving multiple chromosomes (5 cases in Group A and 1 case in Group C), these were excluded from this subanalysis. The remaining incidences were: Group A 58.67% (44/75), Group B 82.54% (52/63), and Group C 78.21% (61/78). Pairwise comparisons showed that Group A differed significantly from both Group B (P = 0.003) and Group C (P = 0.014), while Group B and Group C did not differ significantly (P = 0.534). Among all 222 embryos, only 25 (11.26%) were euploid, significantly lower than in the PGT‑A control group (42.37%, P < 0.001). The 197 abnormal embryos comprised segmental abnormalities (130/222, 58.56%), mixed abnormalities (47/222, 21.17%), aneuploidy (15/222, 6.76%), and amplification failure (5/222, 2.25%) (Fig. 2). Notably, abnormalities in CCRs embryos predominantly arose from segregation errors of parental translocations, whereas those in controls were mainly random aneuploidy. Prenatal diagnosis After thorough counseling and informed consent, blastocysts from Embryo No. 2 (Family 3, Day 6, grade 4BC) and Embryo No. 3 (Family 4, Day 5, grade 4AA) were vitrified and transferred to their respective recipients. The transfer in Family 3 resulted in a singleton pregnancy, whereas the transfer in Family 4 was unsuccessful. Amniocentesis performed at 18–20 weeks of gestation in Family 3 confirmed a normal fetal karyotype, demonstrating concordance among PGT, amniocentesis, and peripheral blood analyses, and ruling out chromosomal abnormalities. Discussion The complexity of CCRs arises not only from the topological diversity of breakpoints but also from their potential to disrupt functional genes or regulatory sequences [20]. This diversity contributes to a wide range of clinical outcomes, from asymptomatic carriage to embryonic lethality, underscoring substantial phenotypic heterogeneity [21]. Therefore, individualized clinical management necessitates the integration of fine-resolution breakpoint analysis with assisted reproductive technologies. During gametogenesis, the primary pathological impact of CCRs is manifested as aberrant chromosomal behavior during meiosis, including disruptions in homologous pairing, synapsis, and segregation. Specifically, CCRs can lead to the loss of homologous sequences near breakpoints, thereby compromising synaptonemal complex assembly and preventing complete synapsis [22]. These disturbances not only elevate the risk of segregation errors but also dramatically reduce the production of balanced gametes [23]. Embryos carrying unbalanced chromosomal translocations often exhibit developmental delay and asynchronous cleavage, leading to implantation failure or early pregnancy loss [24]. Compared to reciprocal translocation carriers, individuals with CCRs show a significantly lower Day 3 embryo formation rate, reflecting a more severely compromised early developmental potential [18]. Moreover, the high-quality blastocyst formation rate is lowest among three-way translocation carriers, underscoring the detrimental impact of such rearrangements on later-stage embryonic development [18]. Notably, certain complex three-way translocations or CCRs are associated with direct developmental arrest and a high incidence of chromosomal mosaicism, both of which may further undermine embryonic genetic integrity and developmental competence [18, 19]. The higher rate of structural abnormalities in our PGT‑A control group likely reflects the high resolution of the DA5000 platform, small‑sample random variation, and patient baseline characteristics (spontaneous abortion or recurrent pregnancy loss), rather than any underlying data abnormality. Consistent with previous reports [17, 18], this study demonstrates that CCR carriers have a significantly lower proportion of high‑quality embryos and a reduced euploidy rate compared to karyotypically normal patients undergoing PGT‑A (P < 0.001), suggesting that CCR‑derived embryos may exhibit fundamental developmental impairments even under identical culture conditions. The detrimental impact of CCRs operates through a dual mechanism: (i) promoting the generation of unbalanced gametes, thereby drastically lowering the proportion of euploid embryos; and (ii) mediating breakpoint‑induced disruption of key genes and alterations in higher‑order chromatin structure, which compromise early embryonic developmental potential beyond the conventional euploid/aneuploid classification [25]. Consequently, CCRs may impair both the genetic integrity and morphological quality of embryos, collectively leading to poorer reproductive outcomes [12]. CCRs are classified into Groups A, B, and C based on complexity. Group A forms stable bivalents or rings, favoring alternate segregation and the production of balanced gametes [26]; therefore, embryonic abnormalities in this group may often arise from random aneuploidy rather than segregation errors [27]. In contrast, Groups B and C harbor multiple breakpoints and derivative chromosomes, leading to the formation of unstable multivalents that hinder chiasma formation and may trigger abnormal segregation patterns (2:1 or 3:1) [28, 29]. This can result in parental‑origin duplications or deletions and may increase the risk of infertility [30]. In line with these observations, our study found no intergroup differences in the rates of high‑quality blastocysts or overall abnormalities, consistent with the findings of Dun Liu et al. [19]. Notably, Group B exhibited the highest morphological quality but also the highest abnormality rate and the lowest normal rate (Fig. 3), suggesting a potential disconnect between morphology and euploidy. Type B double reciprocal translocations may promote good morphology without reducing meiotic errors, potentially leading to nearly all embryos harboring segmental imbalances. These findings point to mechanistic differences among CCR types that may affect both embryo quality and genetic integrity. Group B: Highest morphological quality, but highest abnormality and lowest normal rates These findings establish CCRs as an independent risk factor that impairs reproduction at two distinct levels. At the meiotic level, multiple chromosomal breaks disrupt homologous pairing and force the formation of complex multivalent structures. The highly stochastic segregation of these structures defies the classical balanced/unbalanced gamete model [31], resulting in a paucity of euploid or balanced gametes alongside an abundance of abnormal ones. Concurrently, breakpoints interfere with crossover frequency and distribution, further compromising segregation fidelity. In male carriers, this often manifests as oligozoospermia or azoospermia, limiting the number of embryos available for analysis [32]. At the embryonic stage, breakpoint-induced genomic alterations exert three main effects [6]: (i) direct disruption of key coding sequences; (ii) altered epigenetic regulation near breakpoints; and (iii) aberrant long-range gene regulation through reorganization of topologically associating domains (TADs) [32]. Conclusion Notably, conventional karyotyping cannot accurately identify complex chromosomal rearrangements and may also miss subtle deletions or duplications near breakpoints that disrupt gene function and exacerbate meiotic defects. In summary, CCRs significantly reduce the rate of euploid embryo attainment through multiple interconnected mechanisms. Therefore, for CCR carriers, conventional karyotyping should be complemented with high-resolution breakpoint mapping (e.g., Hi‑C or long‑read sequencing [33]) to enable more accurate reproductive risk assessment and to provide comprehensive molecular markers for PGT, thereby improving the precision of embryo selection. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 : Figure 1. Representative CNVs detection results.(a) Chromosomal analysis of five embryos (1–5) identified one euploid (Embryo 2). Using embryos 1 and 5 as references, the breakpoints of balanced translocations involving chromosomes 5, 8, and 9 were mapped. Abnormalities included trisomy 10 in embryo 3 and copy number alterations at region 10p15.3–p14 in embryo 4. The plot displays copy number variations (red and blue dots at 1 Mb resolution), with the green horizontal line indicating the threshold for abnormality.(b) Chromosomal analysis of five embryos identified one euploid (Embryo 3). Using embryos 1, 2, and 4 as references, the breakpoints of balanced translocations involving chromosomes 1, 6, and 13 were mapped. In addition, embryo 5 was found to carry a mosaic deletion of chromosome 2. The plot displays copy number variations (red and blue dots at 1 Mb resolution), with the green line marking the abnormality threshold. Supplementary Material 2 : Table 1. NGS results for the 14 blastocysts in the present study. Supplementary Material 3 : Table 2. NGS results of the PGT‑A group. Supplementary Material 4 : Table 3. NGS results for previously published CCRs. Author contributions Conducting experiments: YL, YW. Design experiment: LY, PH, XD, and HZ. Collecting patient information: YL, XD, ZL. Embryo biopsy: JS, CW, XZ. Literature search and data analysis: YL, SJ, WL, XT, CZ, LJ, HZ, MH, PH. Writing—original draft preparation: YL. Writing—review and editing: PH, YL. Critical revision for important intellectual content: JL, SH. All authors have read and agreed to the published version of the article. Funding This work was supported by the following grants: the First Batch of the Medical Youth Talent Training Program of Guangxi Zhuang Autonomous Region (to Y.L., The funding project was not assigned a funding number), the Guangxi Key Research and Development Program (grant no. 2023AB22090, to P.H.), and the National Natural Science Foundation of China (grant no. 82160028, to P.H.). Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval This study was approved by the Medical Ethics Committee of Guangxi Maternal and Child Health Hospital (Approval No.: [2023-7]18) and strictly adhered to the ethical principles outlined in the Declaration of Helsinki. All couples provided written informed consent after receiving comprehensive reproductive genetic counseling. Competing interests The authors declare no competing interests. Footnotes Yueyun Lan and Xihe Deng , these authors contributed equally to this work and share first authorship. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hong Zhou, Email: zhouhh2009@126.com. Peng Huang, Email: qfykyb@163.com, Email: endeder@163.com. References Associated Data Supplementary Materials Supplementary Material 1 : Figure 1. Representative CNVs detection results.(a) Chromosomal analysis of five embryos (1–5) identified one euploid (Embryo 2). Using embryos 1 and 5 as references, the breakpoints of balanced translocations involving chromosomes 5, 8, and 9 were mapped. Abnormalities included trisomy 10 in embryo 3 and copy number alterations at region 10p15.3–p14 in embryo 4. The plot displays copy number variations (red and blue dots at 1 Mb resolution), with the green horizontal line indicating the threshold for abnormality.(b) Chromosomal analysis of five embryos identified one euploid (Embryo 3). Using embryos 1, 2, and 4 as references, the breakpoints of balanced translocations involving chromosomes 1, 6, and 13 were mapped. In addition, embryo 5 was found to carry a mosaic deletion of chromosome 2. The plot displays copy number variations (red and blue dots at 1 Mb resolution), with the green line marking the abnormality threshold. Supplementary Material 2 : Table 1. NGS results for the 14 blastocysts in the present study. Supplementary Material 3 : Table 2. NGS results of the PGT‑A group. Supplementary Material 4 : Table 3. NGS results for previously published CCRs. Data Availability Statement No datasets were generated or analysed during the current study.